

CDK2 Antibody
Purified Mouse Monoclonal Antibody
Catalog # AO1691a**Specification****CDK2 Antibody - Product Information**

Application	WB, IHC, FC, ICC, E
Primary Accession	P24941
Reactivity	Human, Mouse
Host	Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	33.9kDa KDa

Description

The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of *S. cerevisiae* cdc28, and *S. pombe* cdc2. It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. This protein associates with and regulated by the regulatory subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Its activity is also regulated by its protein phosphorylation. Two alternatively spliced variants and multiple transcription initiation sites of this gene have been reported.

Immunogen

Purified recombinant fragment of human CDK2 expressed in E. Coli.

Formulation

Purified antibody in PBS with 0.05% sodium azide

CDK2 Antibody - Additional Information

Gene ID 1017

Other Names

Cyclin-dependent kinase 2, 2.7.11.22, Cell division protein kinase 2, p33 protein kinase, CDK2, CDKN2

Dilution

WB~~1/500 - 1/2000

IHC~~1/200 - 1/1000

FC~~1/200 - 1/400

ICC~~N/A

E~~1/10000

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CDK2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

CDK2 Antibody - Protein Information

Name CDK2

Synonyms CDKN2

Function

Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis (PubMed: [10499802](http://www.uniprot.org/citations/10499802) target="_blank">10499802, PubMed: [10884347](http://www.uniprot.org/citations/10884347) target="_blank">10884347, PubMed: [10995386](http://www.uniprot.org/citations/10995386) target="_blank">10995386, PubMed: [10995387](http://www.uniprot.org/citations/10995387) target="_blank">10995387, PubMed: [11051553](http://www.uniprot.org/citations/11051553) target="_blank">11051553, PubMed: [11113184](http://www.uniprot.org/citations/11113184) target="_blank">11113184, PubMed: [12944431](http://www.uniprot.org/citations/12944431) target="_blank">12944431, PubMed: [15800615](http://www.uniprot.org/citations/15800615) target="_blank">15800615, PubMed: [17495531](http://www.uniprot.org/citations/17495531) target="_blank">17495531, PubMed: [19966300](http://www.uniprot.org/citations/19966300) target="_blank">19966300, PubMed: [20935635](http://www.uniprot.org/citations/20935635) target="_blank">20935635, PubMed: [21262353](http://www.uniprot.org/citations/21262353) target="_blank">21262353, PubMed: [21596315](http://www.uniprot.org/citations/21596315) target="_blank">21596315, PubMed: [28216226](http://www.uniprot.org/citations/28216226) target="_blank">28216226, PubMed: [28666995](http://www.uniprot.org/citations/28666995) target="_blank">28666995). Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2 (PubMed: [10499802](http://www.uniprot.org/citations/10499802) target="_blank">10499802, PubMed: [10995386](http://www.uniprot.org/citations/10995386) target="_blank">10995386, PubMed: [10995387](http://www.uniprot.org/citations/10995387) target="_blank">10995387, PubMed: [11051553](http://www.uniprot.org/citations/11051553) target="_blank">11051553, PubMed: [11113184](http://www.uniprot.org/citations/11113184) target="_blank">11113184, PubMed: [12944431](http://www.uniprot.org/citations/12944431) target="_blank">12944431, PubMed: [15800615](http://www.uniprot.org/citations/15800615) target="_blank">15800615, PubMed: [19966300](http://www.uniprot.org/citations/19966300) target="_blank">19966300, PubMed: [20935635](http://www.uniprot.org/citations/20935635) target="_blank">20935635, PubMed: [21262353](http://www.uniprot.org/citations/21262353) target="_blank">21262353, PubMed: [21596315](http://www.uniprot.org/citations/21596315) target="_blank">21596315, PubMed: [28216226](http://www.uniprot.org/citations/28216226) target="_blank">28216226). Triggers duplication of centrosomes and DNA (PubMed: [11051553](http://www.uniprot.org/citations/11051553) target="_blank">11051553). Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus (PubMed: [18372919](http://www.uniprot.org/citations/18372919) target="_blank">18372919, PubMed: [19238148](http://www.uniprot.org/citations/19238148) target="_blank">19238148, PubMed: [19561645](http://www.uniprot.org/citations/19561645) target="_blank">19561645). Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in embryonic stem cells (ESCs) (PubMed: [18372919](http://www.uniprot.org/citations/18372919) target="_blank">18372919, PubMed: [19238148](http://www.uniprot.org/citations/19238148) target="_blank">19238148, PubMed: [19561645](http://www.uniprot.org/citations/19561645) target="_blank">19561645). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA

replication to drive the transition from S phase to mitosis, the G2 phase (PubMed:18372919, PubMed:19238148, PubMed:19561645). EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing (PubMed:20935635). Cyclin E/CDK2 prevents oxidative stress- mediated Ras-induced senescence by phosphorylating MYC (PubMed:19966300). Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis (PubMed:15800615, PubMed:20195506, PubMed:21319273). In response to DNA damage, double- strand break repair by homologous recombination a reduction of CDK2- mediated BRCA2 phosphorylation (PubMed:15800615). Involved in regulation of telomere repair by mediating phosphorylation of NBN (PubMed:28216226). Phosphorylation of RB1 disturbs its interaction with E2F1 (PubMed:10499802). NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication (PubMed:11051553). Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase (PubMed:10995386, PubMed:10995387). Required for vitamin D-mediated growth inhibition by being itself inactivated (PubMed:20147522). Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner (PubMed:20079829). USP37 is activated by phosphorylation and thus triggers G1-S transition (PubMed:21596315). CTNNB1 phosphorylation regulates insulin internalization (PubMed:21262353). Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability (By similarity). Phosphorylates ERCC6 which is essential for its chromatin remodeling activity at DNA double-strand breaks (PubMed:29203878). Acts as a regulator of the phosphatidylinositol 3- kinase/protein kinase B signal transduction by mediating phosphorylation of the C-terminus of protein kinase B (PKB/AKT1 and PKB/AKT2), promoting its activation (PubMed:24670654).

Cellular Location

Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus, Cajal body. Cytoplasm. Endosome Note=Localized at the centrosomes in late G2 phase after separation of the centrosomes but before the start of prophase. Nuclear-cytoplasmic trafficking is mediated during the inhibition by 1,25-(OH)(2)D(3)

CDK2 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)

- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)





Figure 1: Western blot analysis using CDK2 mAb against human CDK2 (AA: 197-295) recombinant protein. (Expected MW is 36.8 kDa)




Figure 2: Western blot analysis using CDK2 mouse mAb against Jurkat (1), HL-60 (2), K562(3), A431(4), HeLa(5), and NIH3T3 (6) cell lysate.




Figure 3: Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using CDK2 mouse mAb with DAB staining.




Figure 4: Immunohistochemical analysis of paraffin-embedded colon cancer tissues using CDK2 mouse mAb with DAB staining.




Figure 5: Immunofluorescence analysis of HeLa cells using CDK2 mouse mAb (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.




Figure 6: Flow cytometric analysis of Jurkat cells using CDK2 mouse mAb (green) and negative control (red).

CDK2 Antibody - References

Eur Arch Otorhinolaryngol. 2009 Oct;266(10):1501-7. Cell Cycle. 2009 Jun 15;8(12):1952-63.